Simbryo is a technology company.
Simbryo has raised $500K across 1 funding round.
Simbryo has raised $500K in total across 1 funding round.
Simbryo Technologies, Inc. is a Houston-based biotech startup founded in 2023 that develops the Simbryo platform, a precision diagnostics tool using endometrial organoids derived from patient stem cells to assess endometrial fertility and improve IVF success rates.[2][3][4] The platform serves fertility specialists and IVF patients facing embryo transfer failures by providing personalized insights into endometrial receptivity through assays like Simbryo FX (direct endometrial function measure), Simbryo Screen (pathology), Simbryo Immuno (inflammation), and Simbryo Omics (implantation window), reducing the need for multiple costly cycles and emotional stress.[1][2][6] It solves the core IVF challenge of uncertain endometrial readiness, where embryo optimization has advanced but uterine factors lag, enabling tailored protocols for higher pregnancy rates; the company shows early growth momentum via partnerships like Cincinnati Children’s Hospital, a $10,000 grant, relocation to LifeSciKY’s Covington lab, and clinical studies at Texas Fertility Center.[2][3][6]
Simbryo was founded in 2023 by Dr. Yael Katz, a scientist driven to address IVF's high failure rates due to endometrial issues, where patients often "hope for the best" without personalized guidance.[3][4] Katz's background in biotechnology led to the creation of endometrial organoids—miniature organ models from patient biopsies—to test receptivity directly, emerging from the need to optimize the understudied uterine side of IVF.[2][3] Early traction includes collaborations with Cincinnati Children’s Hospital, a Bourbon for Science grant from New Riff Distilling, and selection for LifeSciKY’s new 15,000 sq ft wet lab in Covington, KY, announced in September 2025, alongside cancer and immune biotech peers; it's also running predictive clinical studies at Texas Fertility Center.[3][6]
Simbryo rides the wave of organoid medicine and precision reproductive biotech, timing perfectly with IVF market growth amid rising infertility (1 in 6 couples globally) and demand for personalized ART amid stagnant endometrial diagnostics.[2][3] Favorable forces include biotech hub expansions like LifeSciKY’s OneNKY Center, NIH-adjacent grants, and AI/biopharma tools for R&D acceleration, positioning Northern Kentucky as a life sciences node.[3][4] It influences the ecosystem by creating a research biobank/databank for discoveries, partnering with hospitals to standardize receptivity testing, and addressing IVF's 30-40% success gap, potentially reshaping 2M+ annual global cycles toward data-backed outcomes.[2][6]
Simbryo is poised for expansion with its Covington lab move, clinical trial results, and biobank scaling, likely attracting Series A funding and broader clinic adoption by 2026.[3][4] Trends like AI-enhanced omics, organoid standardization, and personalized fertility (e.g., via stem cells) will propel it, evolving its role from IVF optimizer to reproductive medicine leader amid aging populations and ART democratization. As it builds on early Houston roots to national labs, Simbryo exemplifies biotech's shift from embryo hope to endometrial precision, accelerating paths to pregnancy.[2][3]
Simbryo has raised $500K in total across 1 funding round.
Simbryo's investors include DNA Capital, HC9 Ventures, Headwater Ventures, Matchstick Ventures, TSVC Capital.
Simbryo has raised $500K across 1 funding round. Most recently, it raised $500K Seed in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $500K Seed | DNA Capital, HC9 Ventures, Headwater Ventures, Matchstick Ventures, TSVC Capital |